What other stocks do shareholders of ImpediMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX) .

ASX:IPD

ImpediMed (IPD) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IPD Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 1.62 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 3.28%
Price Target: N/A

Stock Analysis

Get ImpediMed alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About ImpediMed Stock (ASX:IPD)

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

IPD Stock News Headlines

March 14, 2024 | finance.yahoo.com

ImpediMed's (ASX:IPD) investors will be pleased with their notable 72% return over the last year

March 11, 2024 | msn.com

Skin in the game: Which ASX director is betting on a lithium recovery?

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 26, 2024 | benzinga.com

Impedimed Stock (OTC:IPDQF) Dividends: History, Yield and Dates

February 20, 2024 | msn.com

How the experts are investing in healthcare-related AI and biotech

February 16, 2024 | msn.com

ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint

February 3, 2024 | morningstar.com

Impedimed Ltd IPD

November 19, 2023 | msn.com

Market Highlights: Wall Street sentiment remains high, 9 most innovative firms, and 5 small caps to watch today

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 19, 2023 | fool.com.au

2 ASX All Ords shares tumbling following leadership shakeups

November 3, 2023 | msn.com

ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)

October 21, 2023 | afr.com

ImpediMed Limited

October 6, 2023 | finance.yahoo.com

Investing in ImpediMed (ASX:IPD) a year ago would have delivered you a 146% gain

September 1, 2023 | finance.yahoo.com

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

August 29, 2023 | finance.yahoo.com

The IPD Group Limited (ASX:IPG) Annual Results Are Out And Analysts Have Published New Forecasts

July 17, 2023 | finance.yahoo.com

Here's Why We're Watching ImpediMed's (ASX:IPD) Cash Burn Situation

July 13, 2023 | finance.yahoo.com

IPD.AX - ImpediMed Limited

July 12, 2023 | au.finance.yahoo.com

IPD.XA - ImpediMed Limited

June 30, 2023 | msn.com

ScoPo’s (actually Wilkie’s) Powerplays: Inoviq soars on clinical data for breast cancer test

May 26, 2023 | msn.com

ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news

April 22, 2023 | msn.com

WILSONS Maintains ImpediMed (ASX:IPD) Overweight Recommendation

April 21, 2023 | msn.com

ScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall, Neuren’s DAYBUE drug officially rolling out in US

April 7, 2023 | finance.yahoo.com

ImpediMed (ASX:IPD) shareholders have earned a 40% CAGR over the last three years

March 31, 2023 | msn.com

ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update

March 27, 2023 | msn.com

Guess which ASX biotech share just rocketed 86% on ‘a major validating moment’

March 26, 2023 | msn.com

ASX Small Caps Lunch Wrap: Who else is having trouble believing their eyes this morning?

March 26, 2023 | msn.com

Top 10 at 10: Cancer fighters, new lithium leaders, and a lucrative takeover offer

See More Headlines

Receive IPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Medical Devices
Sub-Industry: N/A
Current Symbol: ASX:IPD
CUSIP: N/A
CIK: N/A
Web: www.impedimed.com
Phone: 61 7 3860 3700
Fax: N/A
Employees: 76
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: -102.5
Net Income: $-19,500,000.00
Net Margins: -185.47%
Pretax Margin: N/A
Return on Equity: -42.36%
Return on Assets: -27.58%

Debt

Debt-to-Equity Ratio: 2.50
Current Ratio: 7.00
Quick Ratio: 6.23

Sales & Book Value

Annual Sales: $10.47 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.60
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 2,020,000,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 2.94

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Shashi Tripathi
Chief Operating Officer
Dr. Parmjot Bains M.D.
MD, Interim CEO & Director
Mr. McGregor Grant BEc
C.A., FCIS, GAICD, Interim CFO & Executive Director
Mr. Dennis Schlaht
Senior Vice President of R&D and Technology
Lisa Prom
Vice President of Sales
Ms. Joann Yao
Chief Strategy Officer
Dr. Steven Chen M.B.A.
M.D., Chief Medical Center
Ms. Leanne Ralph AAICD
ACIS, BBus, Company Secretary
Dr. Walton A. Taylor
Medical Director

Key Competitors

View All Competitors

Insiders

IPD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ImpediMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX).

This page (ASX:IPD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ImpediMed (IPD) Stock Price, News & Analysis

About ImpediMed Stock (ASX:IPD)

IPD Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

IPD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info